Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03403465 · ClinicalTrials.gov registry record · Phase 2
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
A Phase 2 study of Esophageal Cancer and Vulvar Cancer, sponsored by Duke University.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT03403465 is a Phase 2 study of Esophageal Cancer and Vulvar Cancer that is active but no longer recruiting, run by Duke University. The registered enrollment target is 90 participants, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03403465, a Phase 2 study of Esophageal Cancer and Vulvar Cancer, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This study expands on protocol (NCT01908504"PET adaptive RT") designed to evaluate the utility of adaptive PET-CT planning for radiation therapy (RT). Radiation therapy is used in many malignant diseases as a curative treatment modality. However, critical normal tissue is often in close approximation to disease, and portions of such tissue must receive high doses of radiation for appropriate treatment. Positron Emission Tomography (PET) adapted radiation therapy, as defined in the current protocol, may allow for a means of determining the eventual response to therapy, at a time point when adaptation of treatment plan may be possible to improve outcomes. This protocol will build upon the findings the previous protocol (NCT01908504 "PET adaptive RT") that evaluated the utility of intra-treatment PET imaging in multiple types of cancers. The current focus will be more specific to certain types of gastrointestinal and gynecologic cancers treated with RT, identified from the prior study to warrant further research.
Conditions Studied
Interventions
- OTHER FDG PET scan
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2018-03-27 |
| Est. Completion | 2028-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03403465
The ClinicalTrials.gov registry entry for NCT03403465 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 1 intervention - of which FDG PET scan is the first listed.
NCT03403465 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03403465 about?
NCT03403465 is a clinical study titled "Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers". This study expands on protocol (NCT01908504"PET adaptive RT") designed to evaluate the utility of adaptive PET-CT planning for radiation therapy (RT). Radiation therapy is used in many malignant diseases as a curative treatment modality. However, critical normal tissue is often in close approximatio...
What is the current status of trial NCT03403465?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2018-03-27. Estimated completion is 2028-04-05.
What conditions does trial NCT03403465 study?
This clinical trial studies the following conditions: Esophageal Cancer, Vulvar Cancer, Cancer of the Cervix, Anal Canal Cancer.
What interventions are being tested in trial NCT03403465?
The interventions under investigation include: FDG PET scan (OTHER).
Who is sponsoring clinical trial NCT03403465?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03403465 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
RECRUITING · Phase 2
-
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.